Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford’s mission to counter and constrain global health threats.

The Vice Chancellor with members of the Poonawalla family at the ground breaking ceremony

Located on the University’s Old Road Campus, the Cyrus Poonawalla Vaccines Research Building is a major new facility to host world-class vaccine and pandemic sciences research. Over 9,000m2 of high-quality lab and office space will support research focused on keeping the world safe from infectious disease threats.

The building will bring together over 400 research scientists including from the Jenner Institute, the Pandemic Sciences Institute, the Oxford Vaccine Group, the Department of Paediatrics and the Nuffield Department of Medicine. They will have access to state-of-the-art, highly secure laboratories that can handle a variety of new and emerging pathogens, enabling them to identify potential threats and develop vaccines and treatments to combat them. The building will also be a hub for clinical trials as well as research on epidemiology, surveillance, social and behavioural sciences, policy and ethics.

The groundbreaking ceremony, which was attended by members of the Poonawalla family, began with remarks from Vice-Chancellor Professor Irene Tracey and Martin Staehr from Laing O’Rourke, the company chosen to oversee construction of the building. This was followed by the formal breaking of the soil and a celebratory lunch.

Read the full story on the University of Oxford Development Office website

Similar stories

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders

The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Breakthrough study moves newborn screening for SMA towards nationwide rollout

A major national study led by researchers in the Department of Paediatrics, to evaluate newborn screening for spinal muscular atrophy (SMA) has been funded by the National Institute for Health and Care Research (NIHR), marking a significant milestone towards the potential introduction of SMA screening across the UK.